Evangelos Papachristou

Prof. Dr. Evangelos Papachristou

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
TOTheodora Oikonomaki
Theodora Oikonomaki
MPMarios Papasotiriou
Marios Papasotiriou
TNTheodoros Ntrinias
Theodoros Ntrinias
CKChristina Kalogeropoulou
Christina Kalogeropoulou
PZPetros Zabakis
Petros Zabakis
EPEvangelos Papachristou
Evangelos Papachristou

17 February 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
Stefanos RoumeliotisStefanos Roumeliotis
Stefanos Roumeliotis
INIoannis Eleftherios Neofytou
Ioannis Eleftherios Neofytou
CMCecile Maassen
Cecile Maassen
PLPetra Lux
Petra Lux
KKKonstantia Kantartzi
Konstantia Kantartzi
Vassilios LiakopoulosVassilios Liakopoulos
Vassilios Liakopoulos
We aimed to investigate the association between Red Blood Cell Distribution Width (RDW) and Neutrophil-to-Lymphocyte Ratio (NLR), simple, rapidly assessed markers from the complete blood count with vascular calcification (VC)/stiffness and cardiovascular disease (CVD) in chronic kidney disease (CKD). Dephosphorylated, uncarboxylated matrix Gla-protein (dp-ucMGP), and central/peripheral hemodynamics’ parameters were measured in 158 CKD patients, including Hemodialysis and Peritoneal Dialysis. Spearman’s rho analysis showed that RDW correlated with C-reactive protein (CRP) (r = 0.29, p < 0.001), dp-ucMGP (r = 0.43, p = < 0.0001), central diastolic blood pressure (DBP) (r = −0.19, p = 0.02), and albuminuria (r = −0.17, p = 0.03). NLR correlated with the duration of CVD (r = 0.32, p < 0.001), CRP (r = 0.27, p = 0.01), dp-ucMGP (r = 0.43, p < 0.0001), central DBP (r = −0.32, p < 0.0001) and eGFR (r = −0.25, p = 0.04). In multiple regression models, circulating dp-ucMGP was an independent predictor of RDW (β = 0.001, p = 0.001) and NLR (β = 0.002, p = 0.002). In CKD patients, RDW and NLR are associated with traditional and novel markers of VC and CVD.

Verified
Journal Article
Open access
PDF file
Panagiotis I. GeorgianosPanagiotis I. Georgianos
Panagiotis I. Georgianos
VVVasilios Vaios
Vasilios Vaios
Theodoros EleftheriadisTheodoros Eleftheriadis
Theodoros Eleftheriadis
EPEvangelos Papachristou
Evangelos Papachristou
Vassilios LiakopoulosVassilios Liakopoulos
Vassilios Liakopoulos
Although sodium glucose co-transporter type 2 (SGLT-2) inhibitors were initially introduced as glucose-lowering medications, it was later discovered that cardiorenal protection is the most important treatment effect of these agents. A triad of landmark trials consistently showed the benefits of SGLT-2 inhibitors on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD), irrespective of the presence or absence of Type 2 diabetes (T2D). Furthermore, finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) that safely and effectively improved cardiorenal outcomes in a large Phase 3 clinical trial program that included >13,000 patients with T2D and a wide spectrum of CKD. These two drug categories have shared and distinct mechanisms of action, generating the hypothesis that an overadditive cardiorenal benefit with their combined use may be biologically plausible. In this article, we describe the mechanism of action, and we provide an overview of the evidence for cardiorenal protection with SGLT-2 inhibitors and the nonsteroidal MRA finerenone in patients with CKD associated with T2D.

5 February 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
GGGeorgia Andriana Georgopoulou
Georgia Andriana Georgopoulou
MPMarios Papasotiriou
Marios Papasotiriou
PBPinelopi Bosgana
Pinelopi Bosgana
Anne-Lise de LasticAnne-Lise de Lastic
Anne-Lise de Lastic
ELENI-EVANGELIA KOUFOUELENI-EVANGELIA KOUFOU
ELENI-EVANGELIA KOUFOU
Stelios F. AssimakopoulosStelios F. Assimakopoulos
Stelios F. Assimakopoulos
Background: Systemic inflammation in chronic kidney disease (CKD) is associated (as a cause or effect) with intestinal barrier dysfunction and increased gut permeability, with mechanisms not yet fully understood. This study investigated different parameters of the intestinal barrier in CKD patients, especially tight junction (TJ) proteins and their possible association with systemic endotoxemia and inflammation. Methods: Thirty-three patients with stage I–IV CKD (n = 17) or end-stage kidney disease (ESKD) (n = 16) and 11 healthy controls underwent duodenal biopsy. Samples were examined histologically, the presence of CD3+ T-lymphocytes and the expression of occludin and claudin-1 in the intestinal epithelium was evaluated by means of immunohistochemistry, circulating endotoxin concentrations were determined by means of ELISA and the concentrations of the cytokines IL-1β, IL-6, IL-8, IL-10 and TNF-α in serum were measured using flow cytometry. Results: Patients with stage I–IV CKD or ESKD had significantly higher serum endotoxin, IL-6, IL-8 and IL-10 levels compared to controls. Intestinal occludin and claudin-1 were significantly decreased, and their expression was inversely correlated with systemic endotoxemia. Regarding occludin, a specific expression pattern was observed, with a gradually increasing loss of its expression from the crypt to the tip of the villi. Conclusion: The expression of occludin and claudin-1 in enterocytes is significantly reduced in patients with CKD, contributing to systemic endotoxemia and inflammatory responses in these patients.

1 January 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PKPanagiotis M. Kitrou
Panagiotis M. Kitrou
LBLamprini Balta
Lamprini Balta
EPEvangelos Papachristou
Evangelos Papachristou
MPMarios Papasotiriou
Marios Papasotiriou
KKKonstantinos Katsanos
Konstantinos Katsanos
DKDimitrios Karnabatidis
Dimitrios Karnabatidis

19 February 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Eirini KostopoulouEirini Kostopoulou
Eirini Kostopoulou
DKDimitra Kalavrizioti
Dimitra Kalavrizioti
PDPanagiota Davoulou
Panagiota Davoulou
EPEvangelos Papachristou
Evangelos Papachristou
Xenophon SinopidisXenophon Sinopidis
Xenophon Sinopidis
MPMarios Papasotiriou
Marios Papasotiriou
Inflammation plays a crucial role in diabetes and obesity through macrophage activation. Macrophage chemoattractant protein-1 (MCP-1), activin-A, and clusterin are chemokines with known roles in diabetes and obesity. The aim of this study is to investigate their possible diagnostic and/or early prognostic values in children and adolescents with obesity and type-1 diabetes mellitus (T1DM). Methods: We obtained serum samples from children and adolescents with a history of T1DM or obesity, in order to measure and compare MCP-1, activin-A, and clusterin concentrations. Results: Forty-three subjects were included in each of the three groups (controls, T1DM, and obesity). MCP-1 values were positively correlated to BMI z-score. Activin-A was increased in children with obesity compared to the control group. A trend for higher values was detected in children with T1DM. MCP-1 and activin-A levels were positively correlated. Clusterin levels showed a trend towards lower values in children with T1DM or obesity compared to the control group and were negatively correlated to renal function. Conclusions: The inflammation markers MCP-1, activin-A, and clusterin are not altered in children with T1DM. Conversely, obesity in children is positively correlated to serum MCP-1 values and characterized by higher activin-A levels, which may reflect an already established systematic inflammation with obesity since childhood.